Drug Development Latin America 09

Strategies and Opportunities of Outsourcing of Product Development and Maufacturing Services from Latin America – Business and Technical Perspectives on OTC, Pharmaceutical and Animal Health Products
Daisy Rivera, Senior Director, Established Products Product Licensing, Portfolio Development, Established Products Business Unit, Pfizer, Inc.

Optimizing Oncology Clinical Research in Brazilian Public Hospitals via a Novel Public/Private Collaboration
Frederico Costa, M.D., Director of Clinical Research, Instituto Brasileiro de Pesquisa em Cancer (IBPC)

Challenges and Opportunities of Expansion of Clinical Research into Private Hospitals and Hospitals Outside the Large Metropolitan Centers
Gustavo Kesselring, M.D., President, Brazilian Society for Pharmaceutical Medicine; Director, Clinical Operations, Clinical Research Center, Oswaldo Cruz Hospital, São Paulo Brazil

Challenges in Conducting Clinical Trials in Mexico
Sergio Guerrero, M.D., Director, Medical Research, OCA Hospital/Monterrey International Research Center, Mexico; DIA Board of Directors for Latin America

Registry Studies in Latin America: The Partnership between Academia and Pharmaceutical Industry
Laura Luchini, MD, Ph.D., Clinical Research Unit Director, Brazil, Sanofi-aventis Farmacêutica Ltda.

The Clinical Research Dept in Latin America Subsidiaries of Big Pharma: Headquarters and Country Perspectives
Dalia B. Wajsbrot, Director, Scientific Support, Emergent Markets Business Unit, Pfizer

Feasibility and the Site Selection Challenge: Do We Need a Different Approach for Latin America?
Pedro Garbes-Netto, M.D., M.Sc., Professor, Internal Medicine, Universidade Federal Fluminense and Santa Casa de Misericórdia de São Paulo; Executive Director, GLICO (Grupo Latinoamericano de Investigaciones Clinicas en Oncologia)

Adaptative Designs (Phase I - III): Regulatory Challenges and Opportunities in Latin America
Jorge Rodriguez-Larrain, M.D., FACC, Director Regional Operations, Latin America, Merck & Co., Inc.

PRE-CONFERENCE WORKSHOP 
Optimizing Patient Recruitment in Latin America — Hosted by MMG

VIP NETWORKING DINNER PRESENTATION AND DISCUSSION
Hosted at Porcão Churrascaria

SPECIAL SESSION – REGULATIONS AND TIMELINES FOR CLINICAL TRIALS IN LATIN AMERICA

• Regulatory Framework for Clinical Trials in Chile
  Dr. Eduardo Johnson Rojas, Instituto de Salud Pública de Chile (ISPCH)
• Regulatory Framework for Clinical Trials in Brazil
  Jorge Taveira Samaha, Manager, Clinical Trials Office and New Drugs Approval, ANVISA – Brazil
• Regulatory Framework for Clinical Trials in Argentina
  Dr. Analia Perez, Director, Medical Evaluations, ANMAT – Argentina

INTERACTIVE BREAK-OUT ROUNDTABLE DISCUSSIONS

CHI’s Pharmaceutical Strategy Series is pleased to invite you to attend the inaugural “Drug Development Latin America” being held March 9-10, 2009 at the Hyatt Regency Miami in Miami, FL.

The globalization of R&D into emerging regions continues. Growing R&D spending in these regions has been driven by many factors including the attractiveness of commercial markets there, more favorable economics including lower relative costs for greater speed, access to highly skilled professional labor and a large pool of patients, particularly treatment-naïve ones.
 
Pharmaceutical and biotechnology companies are seeing rapid growth in the volume of their research, development, and clinical trials activity in Latin America. At the same time, this region presents unique challenges that must be anticipated and managed. Join us for this two-day meeting that will include keynotes, case study presentations, interactive panels and roundtable discussions.

We look forward to your attendance in March in Miami.

Very sincerely,

Micah Lieberman